TrialLeukemia & lymphoma2016
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.
Srinivas K Tantravahi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papertrialcites it